CA2540364A1 - Methode destinee a inhiber l'expression de genes de multiresistance aux medicaments et a inhiber la production de proteines resultant de l'expression de ces genes en vue d'ameliorer l'efficacite d'agents chimiotherapeutiques pour le traitement des cancers - Google Patents

Methode destinee a inhiber l'expression de genes de multiresistance aux medicaments et a inhiber la production de proteines resultant de l'expression de ces genes en vue d'ameliorer l'efficacite d'agents chimiotherapeutiques pour le traitement des cancers Download PDF

Info

Publication number
CA2540364A1
CA2540364A1 CA002540364A CA2540364A CA2540364A1 CA 2540364 A1 CA2540364 A1 CA 2540364A1 CA 002540364 A CA002540364 A CA 002540364A CA 2540364 A CA2540364 A CA 2540364A CA 2540364 A1 CA2540364 A1 CA 2540364A1
Authority
CA
Canada
Prior art keywords
cholesterol absorption
absorption inhibitor
phenyl
azetidinone
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002540364A
Other languages
English (en)
Inventor
Kristina Sachs-Barrable
Tatjana Lukic
David John Stewart
Kishor M. Wasan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forbes Medi-Tech Inc
Original Assignee
Forbes Medi-Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forbes Medi-Tech Inc filed Critical Forbes Medi-Tech Inc
Publication of CA2540364A1 publication Critical patent/CA2540364A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CA002540364A 2003-09-26 2004-09-27 Methode destinee a inhiber l'expression de genes de multiresistance aux medicaments et a inhiber la production de proteines resultant de l'expression de ces genes en vue d'ameliorer l'efficacite d'agents chimiotherapeutiques pour le traitement des cancers Abandoned CA2540364A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67305103A 2003-09-26 2003-09-26
US10/673,051 2003-09-26
PCT/CA2004/001697 WO2005030225A2 (fr) 2003-09-26 2004-09-27 Methode destinee a inhiber l'expression de genes de multiresistance aux medicaments et a inhiber la production de proteines resultant de l'expression de ces genes en vue d'ameliorer l'efficacite d'agents chimiotherapeutiques pour le traitement des cancers

Publications (1)

Publication Number Publication Date
CA2540364A1 true CA2540364A1 (fr) 2005-04-07

Family

ID=34393484

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002540364A Abandoned CA2540364A1 (fr) 2003-09-26 2004-09-27 Methode destinee a inhiber l'expression de genes de multiresistance aux medicaments et a inhiber la production de proteines resultant de l'expression de ces genes en vue d'ameliorer l'efficacite d'agents chimiotherapeutiques pour le traitement des cancers

Country Status (9)

Country Link
EP (1) EP1677803A2 (fr)
JP (1) JP2007524651A (fr)
KR (1) KR20060135615A (fr)
CN (1) CN1874780A (fr)
AU (1) AU2004275444A1 (fr)
BR (1) BRPI0414812A (fr)
CA (1) CA2540364A1 (fr)
RU (1) RU2006114049A (fr)
WO (1) WO2005030225A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080021082A (ko) 2005-06-20 2008-03-06 쉐링 코포레이션 히스타민 ｈ3 길항제로서 유용한 피페리딘 유도체
EP2260111B2 (fr) * 2008-03-14 2022-03-23 Genentech, Inc. Variations génétiques associées à une résistance à des médicaments
CN102552284A (zh) * 2011-12-13 2012-07-11 陕西师范大学 麦角甾醇在制备肿瘤多药耐药逆转药物中的应用
US10532088B2 (en) 2014-02-27 2020-01-14 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
JP6728061B2 (ja) 2014-05-05 2020-07-22 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγアゴニストとして用いるテトラヒドロキノリンスルホンアミド及び関連化合物ならびに疾患の治療
CA2982847A1 (fr) 2015-05-05 2016-11-10 Lycera Corporation Sulfonamides de dihydro-2h-benzo[b][1,4]oxazine et composes apparentes destines a etre utilises comme agonistes de ror.gamma. et pour le traitement de maladies
MX2017016134A (es) 2015-06-11 2018-08-15 Lycera Corp Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
CN106420768B (zh) * 2015-08-13 2018-12-28 广州中医药大学第二附属医院 赪酮甾醇作为p-糖蛋白抑制剂的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1439595A (en) * 1993-12-22 1995-07-10 Salk Institute For Biological Studies, The Methods for reducing multidrug resistance
ATE381542T1 (de) * 2001-08-13 2008-01-15 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
AU2003254261B2 (en) * 2002-07-30 2008-04-17 Children's Medical Center Corporation Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors

Also Published As

Publication number Publication date
EP1677803A2 (fr) 2006-07-12
AU2004275444A1 (en) 2005-04-07
JP2007524651A (ja) 2007-08-30
RU2006114049A (ru) 2007-11-20
WO2005030225A2 (fr) 2005-04-07
KR20060135615A (ko) 2006-12-29
CN1874780A (zh) 2006-12-06
BRPI0414812A (pt) 2006-11-14
WO2005030225A3 (fr) 2005-05-26

Similar Documents

Publication Publication Date Title
WO2005042692A2 (fr) Methode permettant d'inhiber l'expression de genes qui induisent l'influx de cholesterol cellulaire dans les cellules animales et d'inhiber la production de proteines issues de l'expression de ces genes
US11319337B2 (en) 3-desoxy derivative and pharmaceutical compositions thereof
CA2968145C (fr) Analogues d'ether phospholipidique utilises en tant que vehicules de medicament ciblant le cancer
EP2744773B1 (fr) Composés d'éthers de bisphénol fluorés et leurs procédés d'utilisation
AU2004255285A1 (en) Novel compounds and compositions comprising sterols and/or stanols and cholesterol biosynthesis inhibitors and use thereof in treating or preventing a variety of diseases and conditions.
JP2014055156A (ja) Ｂｃｌタンパクの結合パートナーとの相互作用を阻害するための化合物および方法
WO2012145328A1 (fr) Composés de dibenzylphényle et leurs méthodes d'utilisation
Xu et al. 2-Methoxy-5 ((3, 4, 5-trimethosyphenyl) seleninyl) phenol inhibits MDM2 and induces apoptosis in breast cancer cells through a p53-independent pathway
CA2540364A1 (fr) Methode destinee a inhiber l'expression de genes de multiresistance aux medicaments et a inhiber la production de proteines resultant de l'expression de ces genes en vue d'ameliorer l'efficacite d'agents chimiotherapeutiques pour le traitement des cancers
JP2022500453A (ja) 線維症、ｎａｓｈ、及び、ｎａｆｌｄを治療する方法での使用のためのトリプトリド、及び、そのプロドラッグ
WO2014048313A1 (fr) Produit de condensation de dérivé théanine et de dérivé coumarine d'acide carboxylique, intermédiaire du produit de condensation, leur procédé de préparation, et leur utilisation
EP3403661B1 (fr) Extrait dérivé d'un organisme marin, composé, et composition à visée médicale ayant une activité de suppression de formation de niches dans les cellules souches leucémiques
ES2390303B1 (es) Compuestos y composiciones para el tratamiento de mieloma múltiple.
WO2012140300A1 (fr) Composés et composition pour le traitement du myélome multiple
ES2390306A1 (es) Compuestos y composiciones para el tratamiento de mieloma múltiple.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued